Experienced in Autism Spectrum Disorder

Lucas Schirmer

Hohe Str. 6, 
Dresden, SN, DE 
Experienced in Autism Spectrum Disorder
Hohe Str. 6, 
Dresden, SN, DE 
OverviewLocationsClinical Research

Overview

Lucas Schirmer practices in Dresden, Germany. Mr. Schirmer is rated as an Experienced expert by MediFind in the treatment of Autism Spectrum Disorder. His top areas of expertise are Multiple Sclerosis (MS), CACH Syndrome, Inclusion Body Myositis, Myositis, and Thrombectomy.

His clinical research consists of co-authoring 83 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Autism Spectrum Disorder.

Gender
Male

Locations

Hohe Str. 6, Dresden, SN 01069, Germany
Other Locations
Ismaninger Str. 22, Munich, BY 81675, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomised Controlled Trial to Compare Ocrelizumab or Alemtuzumab With Autologous Hematopoietic Stem Cell Transplantation (aHSCT) in High Inflammatory Multiple Sclerosis (COAST)
A Randomised Controlled Trial to Compare Ocrelizumab or Alemtuzumab With Autologous Hematopoietic Stem Cell Transplantation (aHSCT) in High Inflammatory Multiple Sclerosis (COAST)
Enrollment Status: Terminated
Publish Date: March 16, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With an Interferon Beta 1a (Avonex®), in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety
A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With an Interferon Beta 1a (Avonex®), in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety
Enrollment Status: Terminated
Publish Date: August 05, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

80 Total Publications

Activated Dendritic Cell Subsets Characterize Muscle of Inclusion Body Myositis Patients and Correlate with KLRG1+ and TBX21+ CD8+ T cells.
Activated Dendritic Cell Subsets Characterize Muscle of Inclusion Body Myositis Patients and Correlate with KLRG1+ and TBX21+ CD8+ T cells.
Journal: medRxiv : the preprint server for health sciences
Published: June 12, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Schirmer's expertise for a condition
ConditionClose
    View All 11 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile